News Home

Does Viridian Therapeutics Inc (VRDN) Have What it Takes to be in Your Portfolio Friday?

Friday, December 02, 2022 03:56 PM | InvestorsObserver Analysts
Does Viridian Therapeutics Inc (VRDN) Have What it Takes to be in Your Portfolio Friday?

The 81 rating InvestorsObserver gives to Viridian Therapeutics Inc (VRDN) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 97 percent of stocks in the Biotechnology industry, VRDN’s 81 overall rating means the stock scores better than 81 percent of all stocks.

Overall Score - 81
VRDN has an Overall Score of 81. Find out what this means to you and get the rest of the rankings on VRDN!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 81 means the stock is more attractive than 81 percent of stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Viridian Therapeutics Inc Stock Today?

Viridian Therapeutics Inc (VRDN) stock is higher by 6.87% while the S&P 500 has fallen -0.25% as of 3:50 PM on Friday, Dec 2. VRDN has risen $1.79 from the previous closing price of $26.04 on volume of 1,080,500 shares. Over the past year the S&P 500 is lower by -11.15% while VRDN has risen 46.47%. VRDN lost -$4.21 per share the over the last 12 months. Click Here to get the full Stock Report for Viridian Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App